openalexCancers2026-07-23
CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions
Cyclin-dependent kinase 4/6 inhibitors have fundamentally changed the management of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. However, these drugs are not interchangeable and the field is moving away from the notion of a uniform “…